(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...

Brendan Wallace has a lot on his mind lately. Wallace is the co-founder of Fifth Wall Ventures, a nine-year-old proptech ...

If you have a tip about tech, startups or the venture industry, contact Troy Wolverton at [email protected] or via ...

The deal would value the firm at about $2 billion and mark the latest push by private equity into the industry.

After a frenetic first couple of weeks as far as big rounds go, this week was quieter than a library. Only one round of more ...

Reports suggest that markets are projected to bounce back, making 2025 one of the strongest years in recent memory for ...

Discover how shrinking markets are forcing VCs to adapt. Will they stick to local ecosystems or compete globally to retain ...

In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...

Discover innovative architecture with Foster + Partners' waterfront towers and transformative projects reshaping cities ...

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

The firm will use the proceeds to advance BE-101 for hemophilia B through clinical proof-of-concept testing and BE-102 for hypophosphatasia into the clinic.

Be Biopharma has secured $92m in a Series C financing round to advance its clinical programmes for haemophilia B and ...